UPLOAD Filing
CERO THERAPEUTICS HOLDINGS, INC.
Date: May 7, 2025 · CIK: 0001870404 · Accession: 0000000000-25-004807
AI Filing Summary & Sentiment
Reasoning
Letter
Re: CERo Therapeutics Holdings, Inc. Preliminary Proxy Statement on Schedule 14A Filed April 25, 2025 Dear Chris Ehrlich:
May 7, 2025
Chris Ehrlich Chief Executive Officer CERo Therapeutics Holdings, Inc. 201 Haskins Way, Suite 230 South San Francisco, CA 94080
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
cc: Jeffrey A. Letalien, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 7, 2025 Chris Ehrlich Chief Executive Officer CERo Therapeutics Holdings, Inc. 201 Haskins Way, Suite 230 South San Francisco, CA 94080 Re: CERo Therapeutics Holdings, Inc. Preliminary Proxy Statement on Schedule 14A Filed April 25, 2025 Dear Chris Ehrlich: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey A. Letalien, Esq. </TEXT> </DOCUMENT>